All In Biotech

Drug Trial Radar · NCT00174707

Study of Docetaxel in Breast Cancer Patients

A Phase III Randomized Study of Sequential Epidoxorubicin Followed By CMF: Cyclophosphamide+Methotrexate+Fluorouracil (Arm A) Versus Sequential Epidoxorubicin Followed By Docetaxel Followed By CMF (Arm B) Versus Sequential Intensified Epidoxorubicin Followed By Docetaxel Followed By High-Dose Cyclophosphamide (Arm C) in Early Breast Cancer Patients With Positive Axillary Lymph Nodes

Last checked: Nov 19, 2026Latest source record: Dec 7, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 998 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

998

Actual

Start

Dec 1997

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objectives: * To compare the disease free survival (DFS) in patients treated with the sequential epidoxorubicin, cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen to that in patients treated with the same treatment plus docetaxel given sequentially after epidoxorubicin Secondary objectives: * To compare the DFS in patients treated with the sequential epidoxorubicin, docetaxel and CMF (only patients with \> or = 4 lymph nodes) regimen to that in patients treated with sequential intensified epidoxorubicin/docetaxel/high dose (HD) cyclophosphamide regimen * To evaluate the overall survival in each arm * To evaluate the tolerability of a sequential intensified epidoxorubicin/docetaxel/HD-cyclophosphamide (arm C) * To compare the safety of a sequential epidoxorubicin/docetaxel/CMF (arm B) regimen versus a standard sequential epidoxorubicin/CMF regimen (arm A)

Conditions

  • Breast Neoplasms

Interventions

  • epidoxorubicine, ciclophosphamide, methotrexate, fluorouracileDrug

    Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)

  • epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracileDrug

    Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)

  • epidoxorubicine, docetaxel, cyclophosphamideDrug

    Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (IDFS) - with exclusion of ductal carcinoma in situ- DCIS- either collateral or ipsilateral, according to STEEP in adjuvant breast cancer trial: Standardized Definitions for Efficacy EndpointsTime frame: Time between randomization date and date of local or distant recurrence or contralateral breast cancer or second primary (non breast) cancer or death from any cause, whichever occurs first

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.